Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

NCT06992440 is registered in ClinicalTrials.gov with Gustavo A Heresi, MD, MS as lead sponsor.

NCT NCT06992440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06992440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Lead sponsor
Gustavo A Heresi, MD, MS
Phase
Phase 2
Overall status
Recruiting
Start date
June 26, 2025
Completion date
September 30, 2030
Enrollment
78 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension